Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Tofacitinib may effectively treat folliculitis decalvans.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

An arthritis drug helped a person with severe hair loss regrow their hair.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.